Abbott has expanded its presence in the vascular market with the acquisition of Walk Vascular, a California-based healthcare technology company known for its thrombectomy solutions. Financial terms of the deal were not made public.
Walk Vascular’s JETi and JETi AIO peripheral thrombectomy systems have both been cleared by the FDA “for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature.” The company was working toward developing a registery of JETi patients at the time of this acquisition. Both systems will be a permanent part of Abbott’s endovascular portfolio going forward.
“The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott's ability to provide one-of-a-kind endovascular therapy solutions to improve patient care,” Julie Tyler, senior vice president of Abbott's vascular business, said in a prepared statement. “Walk Vascular's technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.